Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMichał SekreckiRLRohan LattupallyKLKenny Le

Discussion

Loading...

Member takes

Overview

Observational analysis revealed a gain-of-function mechanism in chronic lymphocytic leukemia and solid tumors, suggesting DCAF16 as a target for new therapies.

Key Points

  • SF3B1 mutations are linked with gain-of-function alterations, increasing DCAF16 protein levels.
  • Gene expression profiling shows specific pathways influenced by DCAF16 in the context of mutant cancers.
  • This approach highlights the therapeutic potential of targeting DCAF16 for treatment of specific cancer types.
  • Solid tumors exhibiting SF3B1 mutations show sensitivity to DCAF16-based therapies, indicating improved options for management.

Cite This Study

Sekrecki et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcc1https://doi.org/10.1182/blood-2025-1474
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SpliceUp: Predicting <i>SF3B1</i> mutations in individual cells via aberrant splice site activation from scRNA-seq data2025 · 2 citations
  2. 2SF3B1 mutations K700E, K666N, and R625H: Gene expression and aberrant splicing consequences2025
  3. 3A Unifying Mechanism for Shared Splicing Aberrations in Splicing Factor Mutant Cancers2025
  4. 4MDS-associated SF3B1 mutations promote aberrant fate choice of hematopoietic stem cell via mis-splicing of mediator kinase module component CDK82025
  5. 5The Impact of Splicing Factor Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Progression2025 · 2 citations